Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults

References

• RushAJKraemerHCSackeimHAReport by the ACNP task force on response and remission in major depressionNeuropsychopharmacol20063118411853
   PubMed Web of Science ®Google Scholar
• HowlandRHChronic depressionHosp Community Psychiatry1993446336398354502
   PubMedGoogle Scholar
• CrownWHFinkelsteinSBerndtERThe impact of treatment-resistant depression on health care utilization and costsJ Clin Psychiatry20026396397112444808
   PubMed Web of Science ®Google Scholar
• DunnerDLRushAJRussellJMProspective long-term multicenter study of the naturalistic outcomes of patients with treatment-resistant depressionJ Clin Psychiatry20066768869516841617
   PubMed Web of Science ®Google Scholar
• HowlandRHHealth status, health care utilization, and medical comorbidity in dysthymiaInt J Psychiatry Med1993232112388270354
   PubMed Web of Science ®Google Scholar
• HowlandRHSchettlerPJRapaportMHClinical features and functioning of patients with minor depressionPsychother Psychosom20087738438918716424
   PubMed Web of Science ®Google Scholar
• KoplanCCharuvastraAComptonMTPrevention psychiatryPsychiatr Ann200737319328
   Google Scholar
• BauneBTAdrianIJacobiFMedical disorders affect health outcome and general functioning depending on comorbid major depression in the general populationJ Psychosomatic Res200762109118
   PubMed Web of Science ®Google Scholar
• CarneyRMFreedlandKETreatment-resistant depression and mortality after acute coronary syndromeAm J Psychiatry200916641041719289455
   PubMed Web of Science ®Google Scholar
• RivelliSJiangWDepression and ischemic heart disease: What have we learned from clinical trials?Curr Opin Cardiol20072228629117556879
   PubMed Web of Science ®Google Scholar
• CarnethonMRBiggsMLBarzilayJILongitudinal association between depressive symptoms and incident type 2 diabetes mellitus in older adultsArch Intern Med200716780280717452543
   PubMed Web of Science ®Google Scholar
• DiemSJBlackwellTLStoneKLDepressive symptoms and rates of bone loss at the hip in older womenJ Am Geriactr Soc200755824831
   PubMed Web of Science ®Google Scholar
• SpernakSMMoorePJHammLFDepression, constructive thinking, and patient satisfaction in cardiac treatment adherencePsychol Health Med20071217218917365898
   PubMedGoogle Scholar
• KilbourneAMReynoldsCFGoodCBSereikaSMJusticeACFineMJHow does depression influence diabetes medication adherence in older patients?Am J Geriat Psychiatry200513202210
   PubMed Web of Science ®Google Scholar
• MohrDCGoodkinDELikoskyWGattoNTreatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosisArch Neurology199754531533
   PubMed Web of Science ®Google Scholar
• SafrenSAHendricksenESMayerKHMimiagaMJPickardROttoMWCognitive-behavioral therapy for HIV medication adherence and depressionCogn Behav Pract200411415424
   Web of Science ®Google Scholar
• KnolMJTwiskJWBeekmanATHeineRJSnoekFJPouwerFDepression as a risk factor for the onset of type 2 diabetes mellitus: A meta-analysisDiabetologia20064983784516520921
   PubMed Web of Science ®Google Scholar
• GoldDTSolimeoSOsteoporosis and depression: A historical perspectiveCurr Osteoporos Rep2006413413917112423
   PubMedGoogle Scholar
• IliasIAlesciSGoldPWChrousosGPDepression and osteoporosis in men: Association or casual link?Hormones2006591616728381
   PubMedGoogle Scholar
• O’KeaneVMarshMSDepression during pregnancyBMJ20073341003100517494021
   PubMed Web of Science ®Google Scholar
• WisnerKLZarinDAHolmboeESRisk-benefit decision making for treatment of depression during pregnancyJAMA200015719331940
   Google Scholar
• RushAJLimitations in efficacy of antidepressant monotherapyJ Clin Psychiatry200768Suppl 1081017900203
   PubMed Web of Science ®Google Scholar
• HamonMBourgoinSPharmacological profile of antidepressants: A likely basis for their efficacy and side effects?Eur Neuropsychopharmacol200616S625S632
   Web of Science ®Google Scholar
• DubocovichMLDrug evaluation: Agomelatine targets a range of major depressive disorder symptomsCurr Opin Investig Drugs20067670680
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyCMHP Assessment Report For Valdoxan. URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/valdoxan/H-915-en6.pdf Accessed November 20, 2008.
   Google Scholar
• European Medicines AgencyCommittee For Medicinal Products For Human Use Summary of Positive Opinion for ValdoxanURL: http://www.emea.europa.eu/pdfs/human/opinion/Valdoxan_57541108en.pdf Accessed November 20, 2008.
   Google Scholar
• European Medicines AgencyValdoxan Product Information. Summary of Product CharacteristicsURL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/valdoxan/H-915-PI-en.pdf
   Google Scholar
• US National Institutes of Health URL: http://www.clinicaltrials.gov
   Google Scholar
• ZlotosDPRecent advances in melatonin receptor ligandsArch Pharm Chem Life Sci2005338229247
   PubMed Web of Science ®Google Scholar
• Wirz-JusticeABiological rhythm disturbances in mood disordersInt Clin Psychopharmacol200621Suppl 1S11S1516436934
   PubMed Web of Science ®Google Scholar
• WehrTAPhotoperiodism in humans and other primates: Evidence and implicationsJ Biol Rhythms20011634836411506380
   PubMed Web of Science ®Google Scholar
• Pandi-PerumalSRSrinivasanVMaestroniGJMCardinaliDPPoeggelerBHardelandRMelatonin: Nature’s most versatile biological signal?FEBS J20062732813283816817850
   PubMed Web of Science ®Google Scholar
• Pandi-PerumalSRSrinivasanVSpenceDWCardinaliDPRole of the melatonin system in the control of sleep: Therapeutic implicationsCNS Drugs200721995101818020480
   PubMed Web of Science ®Google Scholar
• RajaratnamSMWCohenDARogersNLMelatonin and melatonin analoguesSleep Med Clin20094179193
   Google Scholar
• LandoltHPWehrleRAntagonism of serotonergic 5-HT2A/2C receptors: Mutual improvement of sleep, cognition, and mood?Eur J Neurosci2009291795180919473234
   PubMed Web of Science ®Google Scholar
• MillanMJGobertALejeuneFThe novel melatonin agonist agomelatine is an antagonist at 5-hydoxytryptamine-2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathwaysJ Pharmacol Exp Ther200330695496412750432
   PubMed Web of Science ®Google Scholar
• EgertonAAhmadRHiraniEGrasbyPMModulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the ratPsychopharmacology200820048749618597077
   PubMed Web of Science ®Google Scholar
• SheltonRCPapakostasGIAugmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorderActa Psychiatr Scand200811725325918190674
   PubMed Web of Science ®Google Scholar
• Quera-SalvaMAVanierBLaredoJMajor depressive disorder, sleep EEG and agomelatine: An open-label studyInt J Neuropsychopharmacol20071069169617477886
   PubMed Web of Science ®Google Scholar
• KupferDJDepression and associated sleep disturbances: Patient benefits with agomelatineEur Neuropsychopharmacol200616Suppl 5S639S643
   Web of Science ®Google Scholar
• LeproultRVan OnderbergenAL’Hermite-BaleriauxMVan CauterECopinschiGPhase-shifts of 24-h rhythms of hormonal release and body termperature following early evening administration of the melatonin agonist agomelatine in healthy older menClin Endocrinol200563298304
   PubMed Web of Science ®Google Scholar
• DescampsARoussetCMillanMSpeddingMDelagrangePCespuglioRInfluence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecturePsychopharmaology2009200593106
   Web of Science ®Google Scholar
• RacagniGRivaMAPopoliMThe interaction between the internal clock and antidepressant efficacyInt Clin Psychopharmacol200722Suppl 2S9S1417917564
   PubMed Web of Science ®Google Scholar
• DumanRSMonteggiaLMA neurotrophic model for stress-related mood disordersBiol Psychiatry2006591116112716631126
   PubMed Web of Science ®Google Scholar
• SapolskyRMGlucocorticoids and hippocampal atrophy in neuropsychiatric disordersArch Gen Psychiatry20005792593511015810
   PubMed Web of Science ®Google Scholar
• WenkGLParsonsCGDanyszWPotential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: Focus on memantineBehav Pharmacol20061741142416940762
   PubMed Web of Science ®Google Scholar
• HeineVMMaslamSZarenoJJoelsMLucassenPJSuppressed proliferation and apoptotic changes in the rat dentate gyrus after acute and chronic stress are reversibleEur J Neuroscience200419131144
   PubMed Web of Science ®Google Scholar
• EinatHManjiHKCellular plasticity cascades: Genes-to-behavior pathways in animal models of bipolar disorderBiol Psychiatry2006591160117116457783
   PubMed Web of Science ®Google Scholar
• BanasrMSoumierAHeryMMocaerEDaszutaAAgomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesisBiol Psychiatry2007591087109616499883
   PubMed Web of Science ®Google Scholar
• GressensPSchwendimannLHussonIAgomelatine, a melatonin receptor agonist with 5-HT2C receptor antagonist properties, protects the developing murine white matter against excitotoxicityEur J Pharmacol2008588586318466899
   PubMed Web of Science ®Google Scholar
• BarbieroVSZappettiniSMocaerEThe novel antidepressant agomelatine reduces release of glutamate and related presynaptic mechanisms in rat hippocampusEur Neuropyschopharmacol200717Suppl 4S365
   Web of Science ®Google Scholar
• CalabreseFPescaraFRacagniGMocaerEMolteniRRivaMAModulation of Arc and BDNF following acute and chronic administration of agomelatine in ratsEur Neuropyschopharmacol200717Suppl 4S333S334
   Web of Science ®Google Scholar
• SoumierABanasrMLortetSMechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampusNeuropsychopharmacologyDOI: 10.1038/npp.2009.72.
   Google Scholar
• ConboyLTanrikutCZoladzPRThe antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of ratsInt J Neuropsychopharmacol20091232934118706130
   PubMed Web of Science ®Google Scholar
• PaizanisELelievreVSauriniFEffects of agomelatine and fluoxetine on hippocampal cell survival, glucocorticoid receptors, and BDNF expression in a model of depressionEur Neuropyschopharmacol200818Suppl 4S316
   Web of Science ®Google Scholar
• ZupancicMGuilleminaultCAgomelatine: A preliminary review of a new antidepressantCNS Drugs20062098199217140278
   PubMed Web of Science ®Google Scholar
• DolderCRNelsonMSniderMAgomelatine treatment of major depressive disorderAnn Pharmacother2008421822183119033480
   PubMed Web of Science ®Google Scholar
• LooHHaleAD’HaenenHDetermination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: A placebo-controlled dose range studyInt Clin Psychopharmacol20021723924712177586
   PubMed Web of Science ®Google Scholar
• KennedySHEmsleyRPlacebo-controlled trial of agomelatine in the treatment of major depressive disorderEur Neuropsychopharmacol20061629310016249073
   PubMed Web of Science ®Google Scholar
• OlieJPKasperSEfficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorderInt J Neuropsychopharmacol20071066167317477888
   PubMed Web of Science ®Google Scholar
• GoodwinGMEmsleyRRembrySRouillonFfor the Agomelatine Study GroupAgomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized double-blind placebo-controlled trialJ Clin PsychiatryIn Press.
   Web of Science ®Google Scholar
• KennedySHRizviSFultonKRasmussenJA double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XRJ Clin Psychopharmacol20082832933318480691
   PubMed Web of Science ®Google Scholar
• MontejoALPrietoNTerleiraABetter sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers: An 8-week placebo-controlled study using the PRSEXDQ-SALSEX scaleJ Psychopharmacol OnlineFirstDOI:10.1177/0269881108096507 11212008
   Google Scholar
• LemoinePGuilleminaultCAlvarezEImprovement in subjective sleep in major depressive disorder with a novel antidepressant agomelatine: Randomized double-blind comparison with venlafaxineJ Clin Psychiatry2007681723173218052566
   PubMed Web of Science ®Google Scholar
• WulffKBayleFHajakGExploratory study of actigraphic and psychometric measures in depressed patients treated with agomelatine or sertraline (abstract)Eur Neuropsychopharmacol200717Suppl 4S326
   Web of Science ®Google Scholar
• KasperSLaigleLBayleFSuperior antidepressant efficacy of agomelatine versus sertraline: A randomised double-blind study (abstract)Eur Neuropsychopharmacol200818Suppl 4S336S337
   Web of Science ®Google Scholar
• MontgomerySAKennedySHBurrowsGDLejoyeuxMHindmarchIAbsence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation studyInt Clin Psychopharmacol200419527128015289700
   PubMed Web of Science ®Google Scholar
• SteinDJAhokasAAde BodinatCEfficacy of agomelatine in generalized anxiety disorder: A randomized double-blind placebo-controlled studyJ Clin Psychopharmacol20082856156618794654
   PubMed Web of Science ®Google Scholar
• FabianoAde LeersnyderHAgomelatine efficacy on major sleep disturbances in Smith-Magenis syndrome: An exploratory open study in children (abstract)Eur Neuropsychopharmacol.200717Suppl 4S567
   Web of Science ®Google Scholar
• WisniewskiSRRushAJNierenbergAACan phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D reportAm J Psychiatry200916659960719339358
   PubMed Web of Science ®Google Scholar
• HowlandRHThaseMEMood disorders: Therapeutic armamentariumD’haenenHden BoerJAWillnerPBiological PsychiatryLondon, EnglandJohn Wiley & Sons, Ltd2002861875
   Google Scholar
• HowlandRHMedication adherencePsychiatr Ann200838323326
   Web of Science ®Google Scholar
• HowlandRHLimitations of evidence in the practice of evidence-based medicinePsychiatr Ann200838334336
   Web of Science ®Google Scholar
• WisniewskiSRFavaMTrivediMHAcceptability of second-step treatments to depressed outpatients: A STAR*D reportAm J Psychiatry200716475376017475734
   PubMed Web of Science ®Google Scholar
• LooHDaleryJMacherJPPilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders [article in French]Encephale20022835636212232545
   PubMed Web of Science ®Google Scholar
• HowlandRHEvaluating the safety of medications during pregnancy and lactationJ Psychosoc Nurs Ment Health Serv2009471922
   Web of Science ®Google Scholar
• HowlandRHPrescribing psychotropic medications during pregnancy and lactation: Principles and guidelinesJ Psychosoc Nurs Ment Health Serv2009471923
   Web of Science ®Google Scholar
• TrivediMHRushAJGaynesBNMaximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based careNeuropsychopharmacology2007322479248917406651
   PubMed Web of Science ®Google Scholar
• HowlandRHAn overview of seasonal affective disorder and its treatmentThe Physician and SportsmedicineIn Press.
   Web of Science ®Google Scholar
• Pandi-PerumalSRMoscovitchASrinivasanVSpenceDWCardinaliDPBrownGMBidirectional communication between sleep and circadian rhythms and its implications for depression: Lessons from agomelatineProg Neurobiol20098826427119454302
   PubMed Web of Science ®Google Scholar
• CalabreseJRGuelfiJDPerdrizet-ChevallierCAgomelatine adjunctive therapy for acute bipolar depression: Preliminary open dataBipolar Disord2007962863517845278
   PubMed Web of Science ®Google Scholar
• PjrekEWinklerDKonstantinidisAWilleitMPraschak-RiederNKasperSAgomelatine in the treatment of seasonal affective disorderPsychopharmacology200719057557917171557
   PubMed Web of Science ®Google Scholar
• HowlandRHCurrent research in treatment-resistant depression: When to augment and when to switchMedscapeCME Psychiatry and Mental HealthPublished Online July 23, 2009, URL: http://cme.medscape.com/viewarticle/705917
   Google Scholar
• HowlandRHUnderstanding the clinical profile of a drug on the basis of its pharmacology: Mirtazapine as an exampleJ Psychosoc Nurs Ment Health Serv2008461923
   Web of Science ®Google Scholar